Recherche
-
Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes
(Journal of Neurology. vol. 268, n° 3, pp. 879-890, 2021-03)Article de revue -
POMC neuronal heterogeneity in energy balance and beyond: an integrated view
(Nature Metabolism. vol. 3, n° 3, pp. 299-308, 2021-03)Article de revueLibre accès -
Epidemics and outbreaks of peripheral nervous system disorders: II. Toxic and nutritional causes
(Journal of Neurology. vol. 268, n° 3, pp. 892-902, 2021-03)Article de revue -
(Re)contextualizing the Trauma to Prevent or Treat PTSD-Related Hypermnesia
(Chronic Stress. vol. 5, 2021-05-26)Article de revueLibre accès -
Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis.
(Neurobiology of Disease. vol. 160, pp. 105533, 2021-12-01)Article de revueLibre accès -
CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity
(Diabetes. vol. 70, n° 2, pp. 415-422, 2021-02)Article de revue -
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
(CNS drugs. vol. 35, n° 11, pp. 1217-1232, 2021-11)Article de revue -
Vangl2 in the Dentate Network Modulates Pattern Separation and Pattern Completion
(Cell Reports. vol. 31, n° 10, pp. 107743, 2020-06-09)Article de revueLibre accès -
A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
(Annals of Clinical and Translational Neurology. vol. 8, n° 10, pp. 2025-2037, 2021-10)Article de revueLibre accès -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
(Neurology. vol. 8, n° 4, 2021-04-26)Article de revueLibre accès